Ipilimumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ipilimumab: From Melanoma to Choroideremia
One-Sentence Summary
Ipilimumab is an anti-CTLA-4 monoclonal antibody checkpoint inhibitor, globally recognized as a standard treatment for melanoma and several other solid tumors, though it is currently not approved in Taiwan. The TxGNN model predicts it may be effective for Choroideremia with a prediction score of 99.06%; however, this prediction is supported by no clinical trials and no published literature, placing it at the lowest evidence tier (L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not approved in Taiwan — no regulatory data available |
| Predicted New Indication | Choroideremia |
| TxGNN Prediction Score | 99.06% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Ipilimumab (Yervoy) is a fully human IgG1 monoclonal antibody that binds and blocks CTLA-4, a co-inhibitory receptor expressed on activated T-cells. By removing this checkpoint “brake,” ipilimumab allows cytotoxic T-cells to mount a more sustained anti-tumor immune response. This mechanism underpins its regulatory approvals for melanoma, renal cell carcinoma, MSI-H colorectal cancer, and hepatocellular carcinoma in major markets. The drug’s entire therapeutic rationale rests on immune system re-activation in the oncology setting.
Choroideremia, however, is a fundamentally different disease category. It is an X-linked recessively inherited retinal dystrophy caused by loss-of-function mutations in the CHM gene, which encodes Rab Escort Protein 1 (REP1). The resulting defect in vesicle trafficking leads to progressive, irreversible degeneration of the retinal pigment epithelium and photoreceptors — a cell-autonomous, genetically driven process. No established link exists between CTLA-4 checkpoint signaling and CHM-related photoreceptor degeneration.
The high TxGNN score almost certainly reflects indirect topological proximity in the knowledge graph — for example, shared nodes related to retinal pigment epithelium biology or broad immune cell annotations — rather than a true biological or pharmacological relationship. This is a recognized limitation of graph-based AI predictions: high connectivity does not equal mechanistic plausibility. Without any preclinical signal or published hypothesis connecting CTLA-4 blockade to genetic retinal disease, advancing this candidate is not warranted.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Cytotoxicity
Ipilimumab is an antineoplastic immunotherapy; it is not a conventional cytotoxic agent.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy — Anti-CTLA-4 checkpoint inhibitor (monoclonal antibody); not a conventional cytotoxic chemotherapy |
| Myelosuppression Risk | Low (no direct bone marrow suppression; immune-related cytopenias such as immune thrombocytopenia are rare but reported) |
| Emetogenicity Classification | Minimal (IV infusion; nausea is not a primary toxicity concern) |
| Monitoring Items | Liver function tests (LFTs), thyroid function, cortisol/ACTH axis, CBC with differential, serum creatinine, fasting glucose; broad immune-related adverse event (irAE) surveillance required |
| Handling Protection | Standard biologic/monoclonal antibody handling procedures apply; does not require cytotoxic chemotherapy containment protocols |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical or preclinical evidence supporting ipilimumab’s use in choroideremia, and the drug’s established mechanism — CTLA-4 immune checkpoint blockade — has no known relevance to the CHM gene mutation-driven, cell-autonomous retinal degeneration that defines this condition. This prediction is assessed as a knowledge graph topological artifact rather than a biologically plausible repurposing candidate.
To proceed, the following would be needed:
- Demonstration of an immune or inflammatory component in choroideremia pathogenesis that could plausibly be modulated by CTLA-4 blockade
- Preclinical evidence (animal model or in vitro) linking CTLA-4 signaling to REP1 deficiency or retinal pigment epithelium survival
- Any published hypothesis or mechanistic rationale connecting immune checkpoint regulation to inherited retinal dystrophies
- Retrieval of detailed MOA and safety data from DrugBank to complete the drug-level characterization (currently data gap)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.